Today’s 13GD Alert: Vanda Pharmaceuticals Inc Has Another Bullish Trade, Flynn James E Bought Stake!

Today's 13GD Alert: Vanda Pharmaceuticals Inc Has Another Bullish Trade, Flynn James E Bought Stake!

The New Flynn James E Holding in Vanda Pharmaceuticals Inc

Flynn James E filed with the SEC SC 13G/A form for Vanda Pharmaceuticals Inc. The form can be accessed here: 000119380516004039. As reported in Flynn James E’s form, the filler as of late owns 7.94% or 3,435,576 shares of the Health Care–company.

Vanda Pharmaceuticals Inc stake is a new one for the and it was filed because of activity on September 27, 2016. We feel this shows Flynn James E’s positive view for the stock.

Vanda Pharmaceuticals Inc Institutional Sentiment

Latest Security and Exchange filings show 114 investors own Vanda Pharmaceuticals Inc. The institutional ownership in Q3 2015 is high, at 94.93% of the outstanding shares. This is increased by 2663316 the total institutional shares. 41085736 were the shares owned by these institutional investors. In total 24 funds opened new Vanda Pharmaceuticals Inc stakes, 43 increased stakes. There were 13 that closed positions and 31 reduced them.

4 managers had the stock in their top Ten. Notable investors are: Great Point Partners Llc, Armistice Capital Llc, Palo Alto Investors Llc, Deerfield Management Co..

Mitchell Blutt Consonance Capital Management Lp is an institutional investor bullish on Vanda Pharmaceuticals Inc, owning 1436796 shares as of Q3 2015 for 2.28% of its portfolio. William Leland Edwards Palo Alto Investors Llc owns 3997108 shares or 2.17% of its portfolio. CA Venbio Select Advisor Llc have 6.23% of their stock portfolio for 2124593 shares. Further, Deerfield Management Company reported stake worth 2.09% of its US stock portfolio. The CT Great Point Partners Llc owns 1715000 shares. Vanda Pharmaceuticals Inc is 7.65% of the manager’s US portfolio.

Business Profile

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 1.02 in Q2 2016. Its up 0.10, from 0.92 in 2016Q1. The ratio increased, as 19 funds sold all Vanda Pharmaceuticals Inc. shares owned while 33 reduced positions. 19 funds bought stakes while 34 increased positions. They now own 36.20 million shares or 6.54% less from 38.73 million shares in 2016Q1.

First Manhattan Commerce has 200 shares for 0% of their US portfolio. Teachers reported 454,871 shares or 0.01% of all its holdings. Renaissance Technology Ltd holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 151,050 shares. Blackrock Mngmt Lc last reported 147,700 shares in the company. National Bank & Trust Of America Corp De has invested 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Manufacturers Life Company The last reported 26,454 shares in the company. Millennium Management last reported 0.01% of its portfolio in the stock. Proshare Advsrs Ltd Liability Co last reported 0.01% of its portfolio in the stock. Blackrock Fund accumulated 0% or 1.52 million shares. Gemmer Asset Management Ltd Liability Company accumulated 0% or 594 shares. J Goldman Limited Partnership holds 463,900 shares or 0.27% of its portfolio. Vanguard Grp Inc Inc holds 0% or 1.61M shares in its portfolio. Invesco last reported 12,277 shares in the company. Numeric Llc owns 42,900 shares or 0% of their US portfolio. Quantitative Management Ltd Llc last reported 24,400 shares in the company.

Insider Transactions: Since September 15, 2016, the stock had 0 insider buys, and 2 selling transactions for $27.14 million net activity. Flynn James E sold 1.12M shares worth $18.56M.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on November, 1. They expect $-0.15 earnings per share, up 6.25% or $0.01 from last year’s $-0.16 per share. After $-0.04 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 275.00% negative EPS growth.

About 147,247 shares traded hands. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 111.97% since February 29, 2016 and is uptrending. It has outperformed by 99.76% the S&P500.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $727.34 million. The Firm is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders. It currently has negative earnings. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Out of 4 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $22 is the highest target while $15 is the lowest. The $18.25 average target is 11.14% above today’s ($16.42) stock price. Vanda Pharmaceuticals has been the topic of 5 analyst reports since September 2, 2015 according to StockzIntelligence Inc. The rating was initiated by Brean Capital with “Buy” on Wednesday, October 21. The firm has “Market Outperform” rating by JMP Securities given on Friday, August 26. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. The rating was maintained by Piper Jaffray on Wednesday, September 2 with “Buy”.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Reuters.com which released: “Exclusive: Vanda Pharmaceuticals prepares to explore a sale – sources” on September 22, 2016, also Prnewswire.com with their article: “Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results” published on July 27, 2016, Fool.com published: “Why Tiffany, AEP Industries, and Vanda Pharmaceuticals Jumped Today” on August 25, 2016. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Prnewswire.com and their article: “Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial …” published on December 17, 2015 as well as Prnewswire.com‘s news article titled: “Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial …” with publication date: February 10, 2016.

According to Zacks Investment Research, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.”

VNDA Company Profile

Vanda Pharmaceuticals Inc., incorporated on November 13, 2002, is a biopharmaceutical company. The Firm is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment